Genecopoeia, Inc.

Rockville, MD 20850

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $1.05MM
First Award Date 07/02/08
Most Recent Award Date 09/01/10

Key Personnel

Last Name Name Awards Contact
Lin Xinli Henry Lin 5
Li Luyuan Li 2

5 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 09/01/10 - 03/31/12

DESCRIPTION (provided by applicant): a1-antitrypsin (AAT;A1AT) deficiency is a common debilitating hereditary disorder. The condition is characterized by reduced serum levels of AAT, a 52-kDa glycoprotein synthesized chiefly in the liver and, to a lesser extent, by macrophages and neutrophils. AAT acts as an antiprotease and is the physiological...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/01/10 - 04/30/12
PI: Luyuan Li

DESCRIPTION (provided by applicant): TP53 is a transcription factor that exerts tumor suppressor function by regulating the cell cycle, DNA repair and apoptosis. Its transcriptionally active form is a homotetramer consisting of four identical monomeric units. Somatic mutations in the p53 gene are found in over 50% of human cancers and germ line ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 09/01/09 - 08/31/10
PI: Luyuan Li

DESCRIPTION (provided by applicant): TP53 is a transcription factor that exerts tumor suppressor function by regulating the cell cycle, DNA repair and apoptosis. Its transcriptionally active form is a homotetramer consisting of four identical monomeric units. Somatic mutations in the p53 gene are found in over 50% of human cancers and germ line ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-08-050
Budget: 08/01/09 - 01/31/10

DESCRIPTION (provided by applicant): Thrombolytic treatment with plasminogen activators (PA) such as tissue plasminogen activator (tPA) has been used not only for treatment of acute myocardial infarction, but also peripheral arterial occlusion (PAO). However, the risk of life-threatening intracranial hemorrhage is measurably high (0.4- 2.9%), pa...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 07/02/08 - 02/28/09

DESCRIPTION (provided by applicant): The aim of this proposal is to test the feasibility of the use of a p53 fusion protein as a cancer therapeutic. World wide 10 million people are diagnosed every year with cancer. 50% of human cancers involve a mutation in the p53 gene. In addition, these mutations are frequently found in solid tumors that are...